The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.
 
Sonja Loges
Honoraria - Sanofi
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Bristol-Myers Squibb; Chugai Pharma; Lilly; Medac; Novartis; Roche Pharma AG
Speakers' Bureau - Boehringer Ingelheim
Research Funding - BerGenBio; Lilly; Roche Pharma AG
 
Michael Heuser
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Janssen Oncology; Novartis; Pfizer; Stemline Therapeutics
Research Funding - Astellas Pharma (Inst); Bayer (Inst); BerGenBio (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Pfizer (Inst)
 
Jörg Chromik
No Relationships to Disclose
 
Carlos Enrique Vigil
No Relationships to Disclose
 
Peter Paschka
No Relationships to Disclose
 
Francesca RE
No Relationships to Disclose
 
Nicola Di Renzo
No Relationships to Disclose
 
Roberto Lemoli
No Relationships to Disclose
 
Daniele Mattei
No Relationships to Disclose
 
Isabel Ben Batalla
No Relationships to Disclose
 
Monica Hellesøy
No Relationships to Disclose
 
David Micklem
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Robert J Holt
Employment - BerGenBio
 
Katherine Lorens
Employment - BerGenBio
 
James B. Lorens
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Muhammad Shoaib
Consulting or Advisory Role - BerGenBio
 
Hassan Aly
Consulting or Advisory Role - BerGenBio
 
Walter M. Fiedler
Consulting or Advisory Role - Amgen; ARIAD; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Jazz Pharmaceuticals
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst)
 
Bjorn T. Gjertsen
Leadership - Alden Cancer Therapy II; Kinn Therapeutics
Stock and Other Ownership Interests - Alden Cancer Therapy II; Kinn Therapeutics
Consulting or Advisory Role - Astellas Pharma; BerGenBio; Novartis; Seagen
Speakers' Bureau - Pfizer
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Alden Cancer Therapy II patent application in relation to CryoIT trial.
Travel, Accommodations, Expenses - AROG; Astellas Pharma; Novartis; Seagen